Author/contributor
Brian Slater
Partner
Intellectual property partner Brian Slater has been ranked in the 2025 edition of Intellectual Asset Management’s (IAM) Patent 1000: The World’s Leading Patent Professionals for patent litigation in New York. This recognition signals his consistent courtroom success and measurable business value.
The guide is a respected reference for private-practice patent talent. Researchers conduct months of interviews with in-house counsel, peer lawyers, and market observers across more than 60 jurisdictions, then test feedback against public case records and deal data. Only practitioners who show sustained success in demanding disputes and receive strong client feedback feature in the IAM Patent 1000.
With more than twenty-five years steering life sciences and technology patent disputes, Brian has delivered trial wins and favorable settlements for innovators such as Gilead, Merck, Regeneron, and Sanofi. Clients describe him as “a great decision maker” who is “admired for his strategic nous and calm demeanor in pressurized litigation scenarios” and is “brilliant on biosimilars.”
IAM described Brian as an attorney who “excels in the life sciences sector, specializing in helping clients monetise their assets. He combines a deep industry background with a proven track record in litigation.”
He regularly serves as first-chair trial counsel in Hatch-Waxman and other high value life sciences patent disputes, and advises on licensing, due diligence, trade-secret protection, and cross-border enforcement.
“This ranking is a direct credit to our Sterlington team and the trust our clients place in us. We focus on trial-ready strategies that protect innovation and secure commercially sound outcomes.” – Brian Slater
This IAM listing joins other honors for Brian, including rankings in Managing Intellectual Property’s IP Stars and LMG Life Sciences, reflecting broad recognition of his courtroom performance and strategic counsel.